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Dear Editor,
The study by Grmec et al. is encouraging given the very
high mortality of trauma victims who experience out-of-
hospital pulseless electrical activity (PEA) arrest [1, 2]. In
the treatment group there were three interventions: vaso-
pressin, hypertonic saline and hydroxyethyl starch (hyper-
tonic hydroxyethyl starch in the study). However, caution is
to be advocated in the use of hydroxyethyl starch (HES) as
the preferred colloid in this clinical setting. The recently
published VISEPT study (10% 200 kDa/0.5 HES) and
others (10% 200 kDa/0.62 HES) have shown an association
of HES with increased frequency of renal impairment in
sepsis and also in renal transplantation [3–5]. A systematic
review concluded that HES increases the risk of acute renal
failure among patients with sepsis and may also reduce the
probability of survival [6]. With the overwhelming renal
insult from a haemorrhagic PEA arrest, the addition of the
vasoconstrictive effects of vasopressin and an absence of
solid evidence for benefit of HES, it would be better to use
a colloid not associated with renal dysfunction. The newer
starches are smaller, less substituted (130 kDa/0.4) and may
be safer than the ones used in previous studies but the
uncertainty remains.
Fluid replacement is established in controlled haemor-
rhagic shock, but its use in uncontrolled haemorrhagic
shock is still controversial. In traumatic PEA the primary
goal is to restore blood pressure and cardiac output to a
level that can sustain life and prevent secondary cerebral
injury. Given that haemorrhage is the most likely cause of
the PEA, then judicious administration of fluid in combi-
nation with vasopressin is physiologically sound as the shift
in blood away from subdiagphragmatic structures towards
the heart and brain, mediated by the administration of
vasopressin, may not be sufficient on its own to restore
spontaneous circulation. In such an acute extreme patho-
physiological situation it is more likely that the provision of
intravascular volume is more important than the type of
fluid. The debate over crystalloid vs colloid and colloid vs
colloid continues and is now confounded by the increasing
interest in the use of hypertonic saline in trauma.
An international, multicentre, randomised controlled trial
to assess the effects of vasopressin vs saline placebo in pre-
hospital traumatic haemorrhagic shock patients not
responding to standard shock treatment will commence in
January 2009 [Vasopressin in traumatic haemorrhagic
shock (VITRIS.at) study] [7, 8]. The purpose of the trial
is to assess the effect of vasopressin on hospital admission
rate (primary study end point), as well as on haemodynamic
variables, fluid resuscitation requirements and hospital
discharge rate (secondary study end points), in pre-hospital,
presumed traumatic haemorrhage shock patients with a
systolic arterial blood pressure below 90 mmHg after more
than 10 min but less than 30 min of standard shock
treatment by the emergency medical physician [intubation,
crystalloid, colloid and hypertonic saline (up to 4 ml/kg)
fluid resuscitation, and catecholamines (ephedrine, phenyl-
ephrine, norepinephrine)]. The trial is scheduled to com-
plete in April 2011 and the results may obviate the need for
further studies of vasopressin in traumatic PEA.
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